One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-155068
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Dec 4, 2021 |
 Citations: 9 |
Affiliation: University of Chicago, Charité - Universitätsmedizin Berlin, IRCCS Humanitas Research Hospital, Humanitas University, Hospices Civils de Lyon, Claude Bernard University Lyon 1, The University of Texas MD Anderson Cancer Center, Novartis (Switzerland), Oslo University Hospital, Oregon Health & Science University, Vienna General Hospital, Medical University of Vienna, Inserm, Nantes Université, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Institut Català d'Oncologia, Fiona Stanley Hospital, Autonomous University of Barcelona, LMU Klinikum, Ludwig-Maximilians-Universität München, Sarah Cannon, Tennessee Oncology, The Ohio State University, Queen Mary Hospital, Centre Hospitalier Universitaire de Lille, Tohoku University Hospital, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, National University Cancer Institute, Singapore, University of Amsterdam, Amsterdam University Medical Centers, St Vincent's Clinic, UNSW Sydney, St Vincent's Hospital Sydney, University of Sydney, University of Kansas Cancer Center, University Hospital Cologne, University Hospital of Zurich, Tris Pharma (United States), Paracelsus Medical University, University Medical Center Utrecht, UPMC Hillman Cancer Center, University of Pennsylvania, Kyushu University Hospital, Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Mayo Clinic
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
